Cutting-edge solutions

Continuing its tradition of debuting innovative products at the CIIE, Elekta this year is showcasing a full range of precision radiation therapy solutions, including intelligent adaptive radiotherapy platforms and the world's first MRI real-time adaptive radiotherapy solution.

One of the new products is making its Asia debut, Elekta Evo, a single comprehensive solution which gives clinicians the freedom to treat every indication and every patient. With AI-powered high-definition imaging underpinning workflow automation, Elekta Evo can offer both online and offline adaptive radiotherapy, and more highly personalized care.

Another product is making its China debut, Elekta ONE, which provides the latest innovation in oncology software. As an essential part of Elekta Evo, it brings together the best solutions to elevate the user experience with uncompromised treatment quality.

Additionally, the company's booth features two dedicated areas this year. One is for brachytherapy solutions, highlighting the gold standard brachytherapy system for cervical cancer treatment and an X-ray brachytherapy system designed for accessible intraoperative radiotherapy for breast cancer. The other area is for neuroscience solutions, including its latest Gamma Knife, the Elekta Esprit.

"As a leader in precision radiation medicine, we strive to increase accessibility to cancer care, build resilience, and continuously push the boundaries of innovation," Salford said.

The unveiling of these advanced solutions at the CIIE not only reflects Elekta's commitment to addressing the needs of cancer patients but also demonstrate its dedication to fostering collaborations that enhance the healthcare landscape in China. By combining local insights with cutting-edge technology, Elekta aims to deliver personalized solutions that improve patient outcomes and enhance the overall quality of care.

"We are able to unleash the vitality of local innovation while serving the global market with the intelligent practice results in China. The results of these local innovations also have referential value to our global practice, which drives us to continue to innovate and bring more possibilities to cancer treatment," said Salford.